{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:21:39Z","timestamp":1772119299908,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to better understand the patient perspective and treatment experience of relapsed and\/or refractory multiple myeloma (RRMM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This qualitative study enrolled adult RRMM patients from 6 US clinics who had\u2009\u2265\u20093\u00a0months of life expectancy,\u2009\u2264\u20096 prior lines of therapy, and\u2009\u2265\u20091 treatment regimen with a proteasome inhibitor and immunomodulator, or a CD38 monoclonal antibody or an alkylating agent, and a steroid. In-person semi-structured qualitative interviews were conducted to capture concepts that were relevant and important to patients. Topics included RRMM symptoms and impacts and the mode of administration, frequency, duration, convenience, side effects, and overall experience with RRMM treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 22 patients completed interviews. At enrollment, 59.1% of participants were using regimens containing dexamethasone, 36.4% daratumumab, 27.3% carfilzomib, and 18.2% lenalidomide. More participants had experience using intravenous or injectable therapy alone (40.9%) than oral therapy alone (18.2%). Back pain and fatigue were the most frequently reported symptoms (40.9% each); 27.3% reported no symptoms. Most participants reported physical function limitations (86.4%), emotional impacts (77.3%), MM-related activity limitations (72.7%), and sleep disturbances (63.6%). Most participants perceived treatment effectiveness based on physician-explained clinical signs (68.2%) and symptom relief (40.9%). Participants experienced gastrointestinal adverse events (59.1%), fatigue (59.1%), sleep disturbances (31.8%), and allergic reactions (31.8%) with treatment. Key elements of treatment burden included the duration of a typical treatment day (68.2%), treatment interfering with daily activities (54.5%), and infusion duration (50.0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results provide treatment experience\u2013related data to further understand RRMM treatment burden and better inform treatment decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-022-06979-7","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T16:48:09Z","timestamp":1648831689000},"page":"5859-5869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed\/refractory multiple myeloma"],"prefix":"10.1007","volume":"30","author":[{"given":"Nitya","family":"Nathwani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dasha","family":"Cherepanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"France Ginchereau","family":"Sowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"McCarrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"issue":"1","key":"6979_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"key":"6979_CR2","unstructured":"National Cancer Institute. SEER cancer stat facts: myeloma. 2020. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed April 12 2021"},{"issue":"1","key":"6979_CR3","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA et al (2017) Multiple myeloma Nat Rev Dis Primers 3(1):17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46","journal-title":"Multiple myeloma Nat Rev Dis Primers"},{"issue":"9","key":"6979_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A et al (2018) Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol 4(9):1221\u20131227. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2128","journal-title":"JAMA Oncol"},{"key":"6979_CR5","doi-asserted-by":"publisher","unstructured":"Kyle RA, Therneau TM, Rajkumar SV et al (2004) Incidence of multiple myeloma in Olmsted County. Minnesota Cancer 101(11):2667\u20132674. https:\/\/doi.org\/10.1002\/cncr.20652","DOI":"10.1002\/cncr.20652"},{"issue":"1","key":"6979_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu Q, Wei G et al (2021) Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer 21(1):606. https:\/\/doi.org\/10.1186\/s12885-021-08280-y","journal-title":"BMC Cancer"},{"key":"6979_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.606368","volume":"10","author":"L Yamamoto","year":"2021","unstructured":"Yamamoto L, Amodio N, Gulla A, Anderson KC (2021) Harnessing the immune system against multiple myeloma: challenges and opportunities. Front Oncol 10:606368. https:\/\/doi.org\/10.3389\/fonc.2020.606368","journal-title":"Front Oncol"},{"issue":"5","key":"6979_CR8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ et al (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122\u20131128. https:\/\/doi.org\/10.1038\/leu.2013.313","journal-title":"Leukemia"},{"issue":"5","key":"6979_CR9","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516\u20132520. https:\/\/doi.org\/10.1182\/blood-2007-10-116129","journal-title":"Blood"},{"issue":"4","key":"6979_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1172\/JCI129205","volume":"130","author":"SA Minnie","year":"2020","unstructured":"Minnie SA, Hill GR (2020) Immunotherapy of multiple myeloma. J Clin Invest 130(4):1565\u20131575. https:\/\/doi.org\/10.1172\/JCI129205","journal-title":"J Clin Invest"},{"issue":"1","key":"6979_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01542.x","volume":"86","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos MA, San-Miguel JF, Anderson KC (2011) Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 86(1):1\u201315. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01542.x","journal-title":"Eur J Haematol"},{"issue":"4","key":"6979_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bmt.2015.307","volume":"51","author":"RF Cornell","year":"2016","unstructured":"Cornell RF, Kassim AA (2016) Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant 51(4):479\u2013491. https:\/\/doi.org\/10.1038\/bmt.2015.307","journal-title":"Bone Marrow Transplant"},{"key":"6979_CR13","doi-asserted-by":"publisher","unstructured":"MacEwan JP, Majer I, Chou JW, Panjabi S (2021) The value of survival gains from therapeutic innovations for US patients with relapsed\/refractory multiple myeloma. Ther Adv Hematol 12:20406207211027463.\u00a0https:\/\/doi.org\/10.1177\/20406207211027463","DOI":"10.1177\/20406207211027463"},{"issue":"11","key":"6979_CR14","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1634\/theoncologist.2018-0724","volume":"24","author":"A Chari","year":"2019","unstructured":"Chari A, Romanus D, DasMahapatra P et al (2019) Patient-reported factors in treatment satisfaction in patients with relapsed\/refractory multiple myeloma (RRMM). Oncologist 24(11):1479\u20131487. https:\/\/doi.org\/10.1634\/theoncologist.2018-0724","journal-title":"Oncologist"},{"issue":"14","key":"6979_CR15","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/jco.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC et al (2019) Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol 37(14):1228\u20131263. https:\/\/doi.org\/10.1200\/jco.18.02096","journal-title":"J Clin Oncol"},{"issue":"2","key":"6979_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos E, Mikhael J, Hajek R et al (2021) Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J 11(2):40. https:\/\/doi.org\/10.1038\/s41408-021-00432-4","journal-title":"Blood Cancer J"},{"issue":"3","key":"6979_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1586\/17474086.2015.1021772","volume":"8","author":"H Maes","year":"2015","unstructured":"Maes H, Delforge M (2015) Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations. Expert Rev Hematol 8(3):355\u2013366. https:\/\/doi.org\/10.1586\/17474086.2015.1021772","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"6979_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12885-019-5467-x","volume":"19","author":"JA Parsons","year":"2019","unstructured":"Parsons JA, Greenspan NR, Baker NA et al (2019) Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study. BMC Cancer 19(1):264. https:\/\/doi.org\/10.1186\/s12885-019-5467-x","journal-title":"BMC Cancer"},{"issue":"9","key":"6979_CR19","doi-asserted-by":"publisher","first-page":"A451","DOI":"10.1016\/j.jval.2017.08.299","volume":"20","author":"S Bauer","year":"2017","unstructured":"Bauer S, Mueller S, Ratsch B et al (2017) Patient preferences regarding treatment options for relapsed refractory multiple myeloma (RRMM). Value Health 20(9):A451. https:\/\/doi.org\/10.1016\/j.jval.2017.08.299","journal-title":"Value Health"},{"key":"6979_CR20","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.2147\/ppa.S183187","volume":"12","author":"T Wilke","year":"2018","unstructured":"Wilke T, Mueller S, Bauer S et al (2018) Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? Patient Prefer Adherence 12:2387\u20132396. https:\/\/doi.org\/10.2147\/ppa.S183187","journal-title":"Patient Prefer Adherence"},{"issue":"S1","key":"6979_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/01.HS9.0000561152.53784.87","volume":"3","author":"C Kerr","year":"2019","unstructured":"Kerr C, Stubbs K, Trevor N et al (2019) PF717 Quality of life (QOL), perspectives on treatment and important outcomes for multiple myeloma (MM) patients and their carers: a mixed methods evidence synthesis. Hemasphere 3(S1):313\u2013314","journal-title":"Hemasphere"},{"key":"6979_CR22","doi-asserted-by":"publisher","unstructured":"Usmani SZ, Mateos M-V, Hungria V et al (2021) Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. J Cancer Res Clin Oncol 147(2):619\u2013631. https:\/\/doi.org\/10.1007\/s00432-020-03365-w","DOI":"10.1007\/s00432-020-03365-w"},{"issue":"2","key":"6979_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.clml.2017.12.012","volume":"18","author":"P Hari","year":"2018","unstructured":"Hari P, Romanus D, Palumbo A et al (2018) Prolonged duration of therapy is associated with improved survival in patients treated for relapsed\/refractory multiple myeloma in routine clinical care in the United States. Clin Lymphoma Myeloma Leuk 18(2):152\u2013160. https:\/\/doi.org\/10.1016\/j.clml.2017.12.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"6979_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4172\/1948-5956.1000430","volume":"8","author":"GL Mortensen","year":"2016","unstructured":"Mortensen GL, Salomo M (2016) Quality of life in patients with multiple myeloma: a qualitative study. J Cancer Sci Ther 8(12):289\u2013293","journal-title":"J Cancer Sci Ther"},{"issue":"3","key":"6979_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10198-010-0218-6","volume":"12","author":"AC M\u00fchlbacher","year":"2011","unstructured":"M\u00fchlbacher AC, N\u00fcbling M (2011) Analysis of physicians\u2019 perspectives versus patients\u2019 preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma. Eur J Health Econ 12(3):193\u2013203. https:\/\/doi.org\/10.1007\/s10198-010-0218-6","journal-title":"Eur J Health Econ"},{"key":"6979_CR26","unstructured":"United States Census Bureau. U.S. Census Bureau QuickFacts: United States. https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/RHI225219 Accessed April 30 2021"},{"issue":"2","key":"6979_CR27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","volume":"125","author":"PS Rosenberg","year":"2015","unstructured":"Rosenberg PS, Barker KA, Anderson WF (2015) Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity. Blood 125(2):410\u2013412. https:\/\/doi.org\/10.1182\/blood-2014-10-609461","journal-title":"Blood"},{"issue":"2","key":"6979_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","volume":"10","author":"CR Marinac","year":"2020","unstructured":"Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR (2020) Dissecting racial disparities in multiple myeloma. Blood Cancer J 10(2):19. https:\/\/doi.org\/10.1038\/s41408-020-0284-7","journal-title":"Blood Cancer J"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06979-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T05:26:59Z","timestamp":1653542819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06979-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6979"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06979-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-818673\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by Advarra IRB (Columbia, MD). The study was conducted in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NN has no conflicts of interest to disclose. JB and DC were employees of Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA, at the time this research was conducted. PH has received honoraria for consulting from Takeda, BMS, Amgen, Karyopharm, Janssen, and Sanofi. FGS, RS, and KM were employees of Pharmerit \u2013 an OPEN Health Company, at the time the research was conducted.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}